Testing violations of the exponential assumption in cancer clinical trials with survival endpoints.

نویسندگان

  • Gang Han
  • Michael J Schell
  • Heping Zhang
  • Daniel Zelterman
  • Lajos Pusztai
  • Kerin Adelson
  • Christos Hatzis
چکیده

Personalized cancer therapy requires clinical trials with smaller sample sizes compared to trials involving unselected populations that have not been divided into biomarker subgroups. The use of exponential survival modeling for survival endpoints has the potential of gaining 35% efficiency or saving 28% required sample size (Miller, 1983), making personalized therapy trials more feasible. However, the use of exponential survival has not been fully accepted in cancer research practice due to uncertainty about whether or not the exponential assumption holds. We propose a test for identifying violations of the exponential assumption using a reduced piecewise exponential approach. Compared with an alternative goodness-of-fit test, which suffers from inflation of type I error rate under various censoring mechanisms, the proposed test maintains the correct type I error rate. We conduct power analysis using simulated data based on different types of cancer survival distribution in the SEER registry database, and demonstrate the implementation of this approach in existing cancer clinical trials.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

مقایسه مدل شبکه عصبی مصنوعی و رگرسیون پارامتری در پیش‌بینی بقای بیماران مبتلا به سرطان معده

Background & Objective: Using parametric models is common approach in survival analysis. In the recent years, artificial neural network (ANN) models have increasingly used in survival prediction. The aim of this study was to predict of survival rate of patients with gastric cancer by using a parametric regression and ANN models and compare these methods. Methods: We used the data of 436 gast...

متن کامل

New challenges in endpoints for drug development in advanced melanoma.

During the past 3 decades, the field of clinical research for the treatment of advanced melanoma lacked significant advances. Available drugs had low antitumor activity and no proven benefit in overall survival. Recently, new drugs developed based on an in-depth understanding of the biology of this disease have shown significant benefit, with ipilimumab and vemurafenib having recently shown a p...

متن کامل

Alternate endpoints for screening phase II studies.

Phase II trials are screening trials that seek to identify agents with sufficient activity to continue development and those for which further evaluation should be halted. Although definitive phase III trials use progression-free or overall survival to confirm clinical benefit, earlier endpoints are preferable for phase II trials. Traditionally, tumor shrinkage of a predetermined degree (respon...

متن کامل

A Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer

Cancer constitutes a huge burden on societies in countries with any level of economic development. Prostate cancer is the first most diagnosed cancer of men in developed countries and the forth one in developing countries in terms of incidence rate. It is also the third incident cancer of men in Iran along with a prevalence of about 10,000 cases. Castration-resistant prostate cancer (CRPC) is a...

متن کامل

USAGE OF SURROGATE ENDPOINTS IN THE DESIGN AND ANALYSIS OF CLINICAL TRIALS by

There has been a shift in the conduct of early-stage breast cancer trials in recent years from long adjuvant trials with overall or disease-free survival as the efficacy endpoint to shorter neoadjuvant trials with pathological complete response (pCR), a binary marker, at time of surgery as the endpoint. The Food and Drug Administration (FDA) currently embraces this transition and deems evidence...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Biometrics

دوره 73 2  شماره 

صفحات  -

تاریخ انتشار 2017